MDMA-Assisted Therapy for Posttraumatic Stress Disorder: A Mixed-Methods Case Study of a Participant of Color From an Open-Label Trial

Abstract

MDMA (±3,4-methylenedioxymethamphetamine)-assisted therapy (MDMA-AT) was shown in previous clinical trials to have promising efficacy and safety for alleviating treatment-resistant posttraumatic stress disorder (PTSD). However, due to low ethnoracial diversity, the question remains as to whether ethnoracial minority participants would benefit similarly. Thus, a mixed-methods case study was conducted on a participant of color from an open-label trial of MDMA-AT for PTSD to provide a culturally informed lens on symptom recovery with this treatment approach. An additional aim was to elucidate mechanisms of change underlying this treatment for the participant. A case profile was provided, documenting quantitative improvement in PTSD symptoms. This was followed by an interpretative phenomenological analysis (IPA) of effects and mechanisms of action for this participant, based on integration session transcripts. Results of IPA indicated recurrent themes related to psychological mechanisms of symptom change, reduced PTSD symptoms, and additional effects (positive and negative) beyond PTSD symptom reduction. These themes were discussed and recommendations for attuning to culturally relevant material during MDMA-AT were provided.

Keywords

MDMA psychotherapy posttraumatic stress disorder race/ethnicity interpretative phenomenological analysis case study

Get full access to this article

View all access options for this article.

References

Alegría

Fortuna

L. R.

Lin

J. Y.

Norris

F. H.

Gao

Takeuchi

D. T.

Jackson

J. S.

Shrout

P. E.

Valentine

(2013). Prevalence, risk, and correlates of posttraumatic stress disorder across ethnic and racial minority groups in the United States. Medical Care, 51, 1114–1123. https://doi.org/10.1097/MLR.0000000000000007

Amoroso

Workman

(2016). Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to prolonged exposure therapy. Journal of Psychopharmacology, 30, 595–600. https://doi.org/10.1177/0269881116642542

Barone

Beck

Mitsunaga-Whitten

Perl

(2019). Perceived benefits of MDMA-assisted psychotherapy beyond symptom reduction: Qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD. Journal of Psychoactive Drugs, 51, 199–208. https://doi.org/10.1080/02791072.2019.1580805

Beck

A. T.

Steer

R. A.

Brown

G. K.

(1996). Manual for the Beck Depression Inventory-II. Psychological Corporation.

Brown

L. A.

Zandberg

L. J.

Foa

E. B.

(2019). Mechanisms of change in prolonged exposure therapy for PTSD: Implications for clinical practice. Journal of Psychotherapy Integration, 29, 6–14. https://doi.org/10.1037/int0000109

Burge

(2017, August 26). FDA grants breakthrough therapy designation for MDMA-assisted psychotherapy for PTSD, agrees on special protocol assessment for phase trials, 3. https://maps.org/news/media/6786-press-release-fda-grants-breakthrough-therapy-designation-for-mdma-assisted-psychotherapy-for-ptsd,-agrees-on-special-protocol-assessment-for-phase-3-trials

Carhart-Harris

R. L.

Erritzoe

Haijen

Kaelen

Watts

(2018). Psychedelics and connectedness. Psychopharmacology, 235, 547–550. https://doi.org/10.1007/s00213-017-4701-y

Carter

R. T.

(2007). Racism and psychological and emotional injury: Recognizing and assessing race-based traumatic stress. The Counseling Psychologist, 35, 13–105. https://doi.org/10.1177/0011000006292033

Ching

T. H. W.

(2020). Intersectional insights from an MDMA-assisted psychotherapy training trial: An open letter to racial/ethnic and sexual/gender minorities. Journal of Psychedelic Studies, 4, 61–68. https://doi.org/10.1556/2054.2019.017

10.

Descript [Computer software]. (2019). https://www.descript.com

11.

Dolder

P. C.

Müller

Schmid

Borgwardt

S. J.

Liechti

M. E.

(2018). Direct comparison of the acute subjective, emotional, autonomic, and endocrine effects of MDMA, methylphenidate, and modafinil in healthy subjects. Psychopharmacology, 235, 467–479. https://doi.org/10.1007/s00213-017-4650-5

12.

Eustis

E. H.

Cardona

Nauphal

Sauer-Zavala

Rosellini

A. J.

Farchione

T. J.

Barlow

D. H.

(2019). Experiential avoidance as a mechanism of change across cognitive-behavioral therapy in a sample of participants with heterogeneous anxiety disorders. Cognitive Therapy and Research, 44, 275–286. https://doi.org/10.1007/s10608-019-10063-6

13.

Favaro

St Philip

(2021, January 26). Psychedelic drugs can help treat PTSD caused by racism, discrimination: Researchers. CTV National News. https://www.ctvnews.ca/health/psychedelic-drugs-can-help-treat-ptsd-caused-by-racism-discrimination-researchers-1.5283471

14.

Feduccia

A. A.

Jerome

Yazar-Klosinski

Emerson

Mithoefer

M. C.

Doblin

(2019). Breakthrough for trauma treatment: Safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Frontiers in Psychiatry, 10, Article 650. https://doi.org/10.3389/fpsyt.2019.00650

15.

Feduccia

A. A.

Mithoefer

M. C.

(2018). MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms? Progress in Neuropsychopharmacology & Biological Psychiatry, 84, 221–228. https://doi.org/10.1016/j.pnpbp.2018.03.003

16.

Foa

E. B.

Hembree

E. A.

Rothbaum

B. O.

Rauch

S. A. M.

(2019). Prolonged exposure therapy for PTSD: Emotional processing of traumatic experiences therapist guide (2nd ed.). Oxford University Press.

17.

Gary

F. A.

(2005). Stigma: Barrier to mental health care among ethnic minorities. Issues in Mental Health Nursing, 26, 979–999. https://doi.org/10.1080/01612840500280638

18.

George

J. R.

Michaels

T. I.

Sevelius

Williams

M. T.

(2020). The psychedelic renaissance and the limitations of a White-dominant medical framework: A call for indigenous and minority inclusion. Journal of Psychedelic Studies, 4, 4–15. https://doi.org/10.1556/2054.2019.015

19.

Gorman

Belser

A. B.

Jerome

Hennigan

Shechet

Hamilton

Yazar-Klosinski

Emerson

Feduccia

A. A.

(2020). Posttraumatic growth after MDMA-assisted psychotherapy for posttraumatic stress disorder. Journal of Traumatic Stress, 33, 161–170. https://doi.org/10.1002/jts.22479

20.

Green

E. J.

(2008). Individuals in conflict: An internal family systems approach. The Family Journal, 16, 125–131. https://doi.org/10.1177/1066480707313789

21.

Grinspoon

Doblin

(2001). Psychedelics as catalysts of insight-oriented psychotherapy. Social Research, 68, 677–695.

22.

Hayes

S. C.

Wilson

K. G.

Gifford

E. V.

Follette

V. M.

Strosahl

(1996). Experiential avoidance and behavioral disorders: A functional dimensional approach to diagnosis and treatment. Journal of Consulting and Clinical Psychology, 64, 1152–1168. https://doi.org/10.1037/0022-006X.64.6.1152

23.

Hendricks

P. S.

(2018). Awe: A putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. International Review of Psychiatry, 30, 331–342. https://doi.org/10.1080/09540261.2018.1474185

24.

Jerome

Feduccia

A. A.

Wang

J. B.

Hamilton

Yazar-Klosinski

Emerson

Mithoefer

M. C.

Doblin

(2020). Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: A longitudinal pooled analysis of six phase 2 trials. Psychopharmacology, 237, 2485–2497. https://doi.org/10.1007/s00213-020-05548-2

25.

Johansen

P. Ø.

Krebs

T. S.

(2009). How could MDMA (ecstasy) help anxiety disorders? A neurobiological rationale. Journal of Psychopharmacology, 23, 389–391. https://doi.org/10.1177/0269881109102787

26.

Jungaberle

Thal

Zeuch

Rougemont-Bücking

von Heyden

Aicher

Scheidegger

(2018). Positive psychology in the investigation of psychedelics and entactogens: A critical review. Neuropharmacology, 142, 179–199. https://doi.org/10.1016/j.neuropharm.2018.06.034

27.

Kangaslampi

Peltonen

(2019). Mechanisms of change in psychological interventions for posttraumatic stress symptoms: A systematic review with recommendations. Current Psychology, 41, 258–275. https://doi.org/10.1007/s12144-019-00478-5

28.

Kisely

Alichniewicz

K. K.

Black

E. B.

Siskind

Spurling

Toombs

(2017). The prevalence of depression and anxiety disorders in indigenous people of the Americas: A systematic review and meta-analysis. Journal of Psychiatric Research, 84, 137–152. https://doi.org/10.1016/j.jpsychires.2016.09.032

29.

Kline

A. C.

Feeny

N. C.

Zoellner

L. A.

(2020). Race and cultural factors in an RCT of prolonged exposure and sertraline for PTSD. Behaviour Research and Therapy, 132, Article 103690. https://doi.org/10.1016/j.brat.2020.103690

30.

Lerner

Lyvers

(2006). Values and beliefs of psychedelic drug users: A cross-cultural study. Journal of Psychoactive Drugs, 38, 143–147. https://doi.org/10.1080/02791072.2006.10399838

31.

Lester

Artz

Resick

P. A.

Young-Xu

(2010). Impact of race on early treatment termination and outcomes in posttraumatic stress disorder treatment. Journal of Consulting and Clinical Psychology, 78, 480–489. https://doi.org/10.1037/a0019551

32.

Mahony

W. K.

(1987). Perspectives on Krishna’s various personalities. History of Religions, 26, 333–335. https://doi.org/10.1086/463085

33.

McDaniel

(2017). “Strengthening the moral compass”: The effects of MDMA (“ecstasy”) therapy on moral and spiritual development. Pastoral Psychology, 66, 721–741. https://doi.org/10.1007/s11089-017-0789-6

34.

Michaels

T. I.

Purdon

Collins

Williams

M. T.

(2018). Inclusion of people of color in psychedelic assisted psychotherapy: A review of the literature. BMC Psychiatry, 18, Article 245. https://doi.org/10.1186/s12888-018-1824-6

35.

Mithoefer

M. C.

(2016). A manual for MDMA-assisted psychotherapy in the treatment of posttraumatic stress disorder (Version 8). Multidisciplinary Association for Psychedelic Studies.

36.

Mithoefer

M. C.

Feduccia

A. A.

Jerome

Mithoefer

Wagner

Walsh

Hamilton

Yazar-Klosinski

Emerson

Doblin

(2019). MDMA-assisted psychotherapy for treatment of PTSD: Study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology, 236, 2735–2745. https://doi.org/10.1007/s00213-019-05249-5

37.

Neitzke-Spruill

(2020). Race as a component of set and setting: How experiences of race can influence psychedelic experiences. Journal of Psychedelic Studies, 4, 51–60. https://doi.org/10.1556/2054.2019.022

38.

Pérez Benítez

C. I.

Sibrava

N. J.

Kohn-Wood

Bjornsson

A. S.

Zlotnick

Weisberg

Keller

M. B.

(2014). Posttraumatic stress disorder in African Americans: A two year follow-up study. Psychiatry Research, 220, 376–383. https://doi.org/10.1016/j.psychres.2014.07.020

39.

Posner

Brent

Lucas

Gould

Stanley

Brown

Fisher

Zelazny

Burke

Oquendo

Mann

(2008). Columbia-Suicide Severity Rating Scale (C-SSRS). The Research Foundation for Mental Hygiene.

40.

QSR International (Americans) Inc. (2018). NVivo 12 [Computer software].

41.

Richards

W. A.

(2017). Psychedelic psychotherapy: Insights from 25 years of research. Journal of Humanistic Psychology, 57, 323–337. https://doi.org/10.1177/0022167816670996

42.

Riley

D. S.

Barber

M. S.

Kienle

G. S.

Aronson

J. K.

Von Schoen-Angerer

Tugwell

Kiene

Helfand

Altman

D. G.

Sox

Werthmann

P. G.

Moher

Rison

R. A.

Shamseer

Koch

C. A.

Sunn

G. H.

Hanaway

Sudak

N. L.

Kaszkin-Bettag

Carpenter

J. E.

Gagnier

J. J.

(2017). CARE guidelines for case reports: Explanation and elaboration document. Journal of Clinical Epidemiology, 89, 218–235. https://doi.org/10.1016/j.jclinepi.2017.04.026

43.

Roberts

A. L.

Gilman

S. E.

Breslau

Koenen

K. C.

(2011). Race/ethnic differences in exposure to traumatic events, development of post-traumatic stress disorder, and treatment-seeking for post-traumatic stress disorder in the United States. Psychological Medicine, 41, 71–83. https://doi.org/10.1017/S0033291710000401

44.

Schwartz

R. C.

Schwartz

M. F.

Galperin

(2009). Internal family systems therapy. In Courtois

C. A.

Ford

J. D.

(Eds.), Treating complex traumatic stress disorders: An evidence-based guide (pp. 82–104). Guilford Press.

45.

Sessa

(2017). Why psychiatry needs 3,4-methylenedioxymethamphetamine: A child psychiatrist’s perspective. Neurotherapeutics, 14, 741–749. https://doi.org/10.1007/s13311-017-0531-1

46.

Shavers

V. L.

Fagan

Jones

Klein

W. M. P.

Boyington

Moten

Rorie

(2012). The state of research on racial/ethnic discrimination in the receipt of health care. American Journal of Public Health, 102, 953–966. https://doi.org/10.2105/AJPH.2012.300773

47.

Smith

J. A.

Flowers

Larkin

(2009). Interpretative phenomenological analysis: Theory, research, practice. SAGE.

48.

Substance Abuse and Mental Health Services Administration. (2012). Results from the 2011 National Survey on Drug Use and Health: Mental health findings (NSDUH Series H-45, HHS Publication No. [SMA] 12-4725).

49.

Sue

D. W.

Capodilupo

C. M.

Torino

G. C.

Bucceri

J. M.

Holder

A. M.

Nadal

K. L.

Esquilin

M. E.

(2007). Racial microaggressions in everyday life: Implications for counseling. The American Psychologist, 62, 271–286. https://doi.org/10.1037/0003-066X.62.4.271

50.

Suite

D. H.

La Bril

Primm

Harrison-Ross

(2007). Beyond misdiagnosis, misunderstanding and mistrust: Relevance of the historical perspective in the medical and mental health treatment of people of color. Journal of the National Medical Association, 99, 879–885.

51.

Sumnall

H. R.

Cole

J. C.

Jerome

(2006). The varieties of ecstatic experience: An exploration of the subjective experiences of ecstasy. Journal of Psychopharmacology, 20, 670–682. https://doi.org/10.1177/0269881106060764

52.

Tong

Sainsbury

Craig

(2007). Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care, 19, 349–357. https://doi.org/10.1093/intqhc/mzm042

53.

Wagner

A. C.

Mithoefer

M. C.

Mithoefer

A. T.

Monson

C. M.

(2019). Combining cognitive-behavioral conjoint therapy for PTSD with 3,4-methylenedioxymethamphetamine (MDMA): A case example. Journal of Psychoactive Drugs, 51, 166–173. https://doi.org/10.1080/02791072.2019.1589028

54.

Wagner

M. T.

Mithoefer

M. C.

Mithoefer

A. T.

MacAulay

R. K.

Jerome

Yazar-Klosinski

Doblin

(2017). Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy. Journal of Psychopharmacology, 31, 967–974. https://doi.org/10.1177/0269881117711712

55.

Wang

Lin

Bedrosian

Coker

Jerome

Feduccia

Lilienstein

Harrison

Heimler

Mithoefer

Ot’alora

G. M.

Poulter

Carlin

Matthews

Yazar-Klosinski

Emerson

Doblin

(2021). Scaling up: Multi-site open-label clinical trials of MDMA-assisted therapy for severe post-traumatic stress disorder. Journal of Humanistic Psychology. Advance online publication. https://doi.org/10.1177/00221678211023663

56.

Weathers

F. W.

Blake

D. D.

Schnurr

P. P.

Kaloupek

D. G.

Marx

B. P.

Keane

T. M.

(2013a). The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). https://www.ptsd.va.gov/professional/assessment/adult-int/caps.asp

57.

Weathers

F. W.

Blake

D. D.

Schnurr

P. P.

Kaloupek

D. G.

Marx

B. P.

Keane

T. M.

(2013b). The Life Events Checklist for DSM-5 (LEC-5). https://www.ptsd.va.gov/professional/assessment/te-measures/life_events_checklist.asp

58.

Wiedemann

Stott

Nickless

Beierl

E. T.

Wild

Warnock-Parkes

Grey

Clark

D. M.

Ehlers

(2020). Cognitive processes associated with sudden gains in cognitive therapy for posttraumatic stress disorder in routine care. Journal of Consulting and Clinical Psychology, 88, 455–469. https://doi.org/10.1037/ccp0000488

59.

Williams

M. T.

Labate

B. C.

(2020). Diversity, equity, and access in psychedelic medicine. Journal of Psychedelic Studies, 4, 1–3. https://doi.org/10.1556/2054.2019.03

60.

Williams

M. T.

Reed

S. J.

Aggarwal

(2020). Culturally informed research design issues in a study for MDMA-assisted psychotherapy for posttraumatic stress disorder. Journal of Psychedelic Studies, 4, 40–50. https://doi.org/10.1556/2054.2019.016